Drugs / Lenzumestrocel
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06676423 | Nov 2022 → Nov 2023 | amyotrophic lateral sclerosis | Corestemchemon, Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04745299 | Feb 2021 → Oct 2024 | amyotrophic lateral sclerosis | Corestemchemon, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lenzumestrocel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04745299 ↗ |
| Modality | Cell therapy | “Lenzumestrocel is the orphan cell therapy product for ALS” PMID 35585556 ↗ May 2022 |